ACAD Q4 2020 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121M+23.1% YoY

Gross Profit

$116M95.6% margin

Operating Income

-$67M-55.5% margin

Net Income

-$67M-55.2% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+0.4%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$29M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$783M

Total Liabilities

$156M

Stockholders' Equity

$627M

Cash & Equivalents

$326M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$98M	+23.1%
Gross Profit	$116M	$93M	+24.4%
Operating Income	-$67M	-$56M	-19.1%
Net Income	-$67M	-$53M	-25.9%